Menu
Menu
Glenmark Pharmaceuticals has reached a new milestone, with its stock hitting an all-time high of Rs 1,576 per share following a robust Q1 FY25 earnings report. The company posted a 34.5% YoY increase in Ebitda and strong revenue growth, particularly in the Indian market. Explore how Glenmarkâs impressive financial performance and strategic initiatives are driving investor confidence and shaping its future prospects.
In a groundbreaking development, Glenmark Pharmaceuticals has secured USFDA approval to market generic Topiramate Capsules, a pivotal medication for managing seizures and epilepsy. This approval underscores Glenmark's commitment to expanding healthcare access through affordable alternatives, while maintaining therapeutic equivalence to the branded version. Explore how this milestone enhances treatment options and reshapes the pharmaceutical landscape.